TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01713569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT00391391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: Vaccine (children dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Description: Vaccine (infant dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Description: Vaccine (children dose)
Study: NCT04708132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw retained restoration
Description: Hybrid prosthesis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant-retained ball overdentures
Description: Removable prosthesis
Study: NCT05588037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS +PPV+IOL + air
Description: The procedures are combined the FLACS +PPV+IOL + air.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex
Description: The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS + PPV+IOL + internal limiting membrane peeling + air
Description: The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS + PPV+IOL
Description: The procedures are combined the FLACS + PPV+IOL.
Study: NCT00792532

Intervention type: PROCEDURE
Intervention: interventional MRI for implantation of DBS electrodes
Description: DBS implantation will be performed entirely within a Phillips 3T MRI scanner

Intervention type: DEVICE
Intervention: DBS electrodes
Description: Deep brain stimulation (DBS) electrodes
Study: NCT03059771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Enhancement of Motivation (MEMS)
Description: The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will only engage in a goal-setting session.
Study: NCT01386268

Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
Study: NCT02784600

Intervention type: DEVICE
Intervention: Bioinductive implant
Study: NCT01790555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namisol

Intervention type: DRUG
Group type: OTHER
Intervention: Diazepam/placebo
Study: NCT01011972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1107
Description: 6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
Study: NCT02331979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Neuromodulation
Description: Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Neuromodulation
Description: Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Neuromodulation
Description: Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
Study: NCT01557959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic linkage analysis
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT01897649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB06
Description: 15g/day NUTRIOSE FB06

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLUCIDEX 21
Description: 15g/day GLUCIDEX 21
Study: NCT04170270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours.
Study: NCT04630717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical hypnosis session
Description: the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control groupe
Description: the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
Study: NCT04502121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXPECT: Preoperative optimization of cardiac valve patient's expectations
Description: The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
Study: NCT01983124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fotemustine + Vemurafenib
Description: Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity.
Study: NCT00993499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin)
Description: Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
Study: NCT03908827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Mineral Aspirate Concentrate (BMAC)
Description: A single BMAC injection will be performed into the arthritic joint
Study: NCT01922375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil
Study: NCT03510351

Intervention type: DRUG
Intervention: Ceftolozane-Tazobactam
Description: Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
Study: NCT00334282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral pazopanib tablet 800 mg once daily continuously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo (800 mg tablet) once daily
Study: NCT03052140

Intervention type: DEVICE
Group type: OTHER
Intervention: Lamelleye Dry Eye Drops
Description: Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lamelleye Dry Eye Drops
Description: Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optive Plus
Description: Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye

Intervention type: DEVICE
Group type: OTHER
Intervention: Optive Plus
Description: Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
Study: NCT02623075

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
Study: NCT03558074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK4290
Description: ALK4290 400 mg tablet twice a day
Study: NCT00453973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
Study: NCT02978183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Study: NCT01794273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine and phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine and phenylephrine
Study: NCT03831698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid ethyl esters (2 gram)
Description: Omega-3 fatty acid ethyl esters (2 gram)
Study: NCT02695004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310
Study: NCT00689754

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube placement
Description: standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
Study: NCT03328416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
Study: NCT01363934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.
Study: NCT03351582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grief and Communication Family Intervention
Description: This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grief and Communication Family Intervention
Description: This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
Study: NCT02695004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKF-310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00125723

Intervention type: OTHER
Group type: OTHER
Intervention: PI Discretion
Description: PI Discretion

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: PI Discretion
Description: PI Discretion
Study: NCT02647333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-6 Fatty Acid
Description: Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
Study: NCT00998517

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy/peanut fortified spread
Description: 75kcal/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk fortified corn/soy blend
Description: 75 kcal/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Plumpy®
Description: 75 kcal/kg/day
Study: NCT00583388

Intervention type: DIETARY_SUPPLEMENT
Intervention: L-arginine
Description: Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
Study: NCT03152435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR CART
Description: EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
Study: NCT00665249

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: See MotivationalInterviewing.org

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirit-Only Motivational Interviewing
Description: Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
Study: NCT01948973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is here set to 90% of the sensory threshold
Study: NCT00665249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Change
Description: Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
Study: NCT01363934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1113
Description: Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
Study: NCT01948973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subsensory
Description: The stimulation is here set to 90% of the sensory threshold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is here turned OFF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFF
Description: The stimulation is here turned OFF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprasensory
Description: The stimulation is here set suprasensory

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprasensory
Description: The stimulation is here set suprasensory
Study: NCT00833066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 25µg of gpASIT+TM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo entero-coated capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 100µg of gpASIT+TM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: entero-coated capsules containing 400µg of gpASIT+TM
Study: NCT02995018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.